Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 580 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... January 9, 2023 NALIRIFOX Improves Survival Compared with Nab-paclitaxel Plus Gemcitabine in First-Line Treatment... September 22, 2023 How Finding the Right Primary Care Physician During Cancer Has Helped... March 24, 2021 Alectinib Approved as an Adjuvant Treatment for Lung Cancer May 8, 2024 Load more HOT NEWS EMA Recommends Extension of Indications for Avelumab ESMO’s Expert Consensus: Do Not Discontinue or Delay Cancer Treatment That... Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with... Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That...
